Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Eli Lilly is licensing Sangamo Therapeutics’ AAV capsid for an undisclosed CNS disease target, and the $18 million upfront fee should give the beleaguered biotech a much-needed cash injection. The deal centers on Sangamo’s STAC ...